CIBC World Markets Inc. boosted its stake in Zoetis Inc (NYSE:ZTS) by 290.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 107,751 shares of the company’s stock after purchasing an additional 80,181 shares during the quarter. CIBC World Markets Inc.’s holdings in Zoetis were worth $8,998,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in ZTS. Advisory Services Network LLC lifted its stake in Zoetis by 42.4% in the 4th quarter. Advisory Services Network LLC now owns 2,423 shares of the company’s stock worth $175,000 after purchasing an additional 721 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its stake in Zoetis by 49.6% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 54,241 shares of the company’s stock worth $3,908,000 after purchasing an additional 17,973 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Zoetis by 3,106.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,163 shares of the company’s stock worth $372,000 after purchasing an additional 5,002 shares in the last quarter. Virtu Financial LLC lifted its stake in Zoetis by 19.8% in the 4th quarter. Virtu Financial LLC now owns 14,005 shares of the company’s stock worth $1,009,000 after purchasing an additional 2,313 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in Zoetis by 227.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 540,047 shares of the company’s stock worth $38,905,000 after purchasing an additional 375,347 shares in the last quarter. Institutional investors and hedge funds own 90.09% of the company’s stock.
ZTS has been the topic of a number of research reports. Jefferies Financial Group set a $97.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, February 26th. Cantor Fitzgerald set a $98.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Wednesday, June 6th. Craig Hallum restated a “buy” rating and issued a $94.00 target price (up from $87.00) on shares of Zoetis in a report on Wednesday, April 25th. Citigroup restated a “buy” rating and issued a $98.00 target price (up from $85.00) on shares of Zoetis in a report on Thursday, April 19th. Finally, ValuEngine upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $84.73.
Shares of Zoetis opened at $87.00 on Thursday, MarketBeat Ratings reports. The stock has a market cap of $43.03 billion, a P/E ratio of 36.25, a PEG ratio of 1.96 and a beta of 0.98. Zoetis Inc has a 12 month low of $59.50 and a 12 month high of $89.25. The company has a debt-to-equity ratio of 2.51, a quick ratio of 2.83 and a current ratio of 4.27.
Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Wednesday, May 2nd. The company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.69 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.35 billion. Zoetis had a net margin of 17.97% and a return on equity of 68.51%. The firm’s revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.53 EPS. equities analysts forecast that Zoetis Inc will post 3.06 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 4th. Investors of record on Friday, July 20th will be issued a dividend of $0.126 per share. The ex-dividend date is Thursday, July 19th. This represents a $0.50 annualized dividend and a yield of 0.58%. Zoetis’s payout ratio is 20.83%.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.